Vyome Holdings, Inc. Asset Resilience Ratio
Vyome Holdings, Inc. asset resilience ratio. Vyome Holdings, Inc. (HIND) has an Asset Resilience Ratio of 5.51% as of December 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See HIND days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Vyome Holdings, Inc. (2006–2018)
Asset resilience ratio of Vyome Holdings, Inc. from 2006 to 2018. This chart shows how Vyome Holdings, Inc.'s Asset Resilience Ratio has changed over time. Read HIND total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Vyome Holdings, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see HIND current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.55 Million | 5.51% |
| Total Liquid Assets | $2.55 Million | 5.51% |
Asset Resilience Insights
- Limited Liquidity: Vyome Holdings, Inc. maintains only 5.51% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Vyome Holdings, Inc. Industry Peers by Asset Resilience Ratio
Compare Vyome Holdings, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Vyome Holdings, Inc. Asset Resilience Ratio by Year (2006–2018)
Vyome Holdings, Inc. asset resilience ratio by year from 2006 to 2018. The table below shows the annual Asset Resilience Ratio data for Vyome Holdings, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 5.51% | $2.55 Million | $46.27 Million | -20.75pp |
| 2017-12-31 | 26.26% | $23.29 Million | $88.70 Million | -9.25pp |
| 2016-12-31 | 35.51% | $2.50 Million | $7.04 Million | -43.68pp |
| 2015-12-31 | 79.18% | $9.18 Million | $11.59 Million | +76.09pp |
| 2011-12-31 | 3.09% | $1.01 Million | $32.49 Million | -15.43pp |
| 2008-12-31 | 18.53% | $5.24 Million | $28.28 Million | +4.48pp |
| 2007-12-31 | 14.05% | $8.30 Million | $59.05 Million | -33.63pp |
| 2006-12-31 | 47.68% | $17.20 Million | $36.06 Million | -- |
About Vyome Holdings, Inc.
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinica… Read more